vs
ESCALADE INC（ESCA）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是ESCALADE INC的1.2倍（$75.5M vs $62.6M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -2.2%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $13.7M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 4.5%）
Escalade Inc是一家专业体育用品制造及分销商，主营篮球架、射箭装备、乒乓球器材、游戏桌及户外休闲配件，核心市场覆盖北美、欧洲及亚太地区，服务客户涵盖零售消费、商业健身、专业体育分销等领域。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
ESCA vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.2倍
$62.6M
营收增速更快
PBYI
高出29.9%
-2.2%
自由现金流更多
PBYI
多$732.0K
$13.7M
两年增速更快
PBYI
近两年复合增速
4.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $62.6M | $75.5M |
| 净利润 | $3.7M | — |
| 毛利率 | 27.7% | 69.3% |
| 营业利润率 | 8.2% | 22.7% |
| 净利率 | 5.9% | — |
| 营收同比 | -2.2% | 27.7% |
| 净利润同比 | 37.1% | — |
| 每股收益（稀释后） | $0.27 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESCAPBYI
| Q4 25 | $62.6M | $75.5M | ||
| Q3 25 | $67.8M | $54.5M | ||
| Q2 25 | $54.3M | $52.4M | ||
| Q1 25 | $55.5M | $46.0M | ||
| Q4 24 | $63.9M | $59.1M | ||
| Q3 24 | $67.7M | $80.5M | ||
| Q2 24 | $62.5M | $47.1M | ||
| Q1 24 | $57.3M | $43.8M |
净利润ESCAPBYI
| Q4 25 | $3.7M | — | ||
| Q3 25 | $5.6M | $8.8M | ||
| Q2 25 | $1.8M | $5.9M | ||
| Q1 25 | $2.6M | $3.0M | ||
| Q4 24 | $2.7M | — | ||
| Q3 24 | $5.7M | $20.3M | ||
| Q2 24 | $2.8M | $-4.5M | ||
| Q1 24 | $1.8M | $-4.8M |
毛利率ESCAPBYI
| Q4 25 | 27.7% | 69.3% | ||
| Q3 25 | 28.1% | 77.7% | ||
| Q2 25 | 24.7% | 76.5% | ||
| Q1 25 | 26.7% | 77.1% | ||
| Q4 24 | 24.9% | 76.4% | ||
| Q3 24 | 24.8% | 63.9% | ||
| Q2 24 | 24.2% | 77.4% | ||
| Q1 24 | 25.0% | 75.5% |
营业利润率ESCAPBYI
| Q4 25 | 8.2% | 22.7% | ||
| Q3 25 | 10.8% | 17.6% | ||
| Q2 25 | 4.8% | 12.7% | ||
| Q1 25 | 6.6% | 8.7% | ||
| Q4 24 | 7.1% | 22.6% | ||
| Q3 24 | 11.8% | 27.4% | ||
| Q2 24 | 7.1% | -4.6% | ||
| Q1 24 | 5.3% | -5.3% |
净利率ESCAPBYI
| Q4 25 | 5.9% | — | ||
| Q3 25 | 8.2% | 16.2% | ||
| Q2 25 | 3.4% | 11.2% | ||
| Q1 25 | 4.7% | 6.5% | ||
| Q4 24 | 4.2% | — | ||
| Q3 24 | 8.4% | 25.2% | ||
| Q2 24 | 4.5% | -9.6% | ||
| Q1 24 | 3.1% | -11.0% |
每股收益（稀释后）ESCAPBYI
| Q4 25 | $0.27 | $0.26 | ||
| Q3 25 | $0.40 | $0.17 | ||
| Q2 25 | $0.13 | $0.12 | ||
| Q1 25 | $0.19 | $0.06 | ||
| Q4 24 | $0.20 | $0.40 | ||
| Q3 24 | $0.40 | $0.41 | ||
| Q2 24 | $0.20 | $-0.09 | ||
| Q1 24 | $0.13 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $97.5M |
| 总债务越低越好 | $18.5M | $22.7M |
| 股东权益账面价值 | $173.2M | $130.3M |
| 总资产 | $222.1M | $216.3M |
| 负债/权益比越低杠杆越低 | 0.11× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资ESCAPBYI
| Q4 25 | — | $97.5M | ||
| Q3 25 | — | $94.4M | ||
| Q2 25 | — | $96.0M | ||
| Q1 25 | — | $93.2M | ||
| Q4 24 | — | $101.0M | ||
| Q3 24 | — | $96.7M | ||
| Q2 24 | — | $96.8M | ||
| Q1 24 | — | $107.2M |
总债务ESCAPBYI
| Q4 25 | $18.5M | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | $25.6M | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益ESCAPBYI
| Q4 25 | $173.2M | $130.3M | ||
| Q3 25 | $172.3M | $115.3M | ||
| Q2 25 | $168.3M | $104.7M | ||
| Q1 25 | $168.8M | $97.1M | ||
| Q4 24 | $169.0M | $92.1M | ||
| Q3 24 | $170.1M | $71.1M | ||
| Q2 24 | $166.0M | $48.5M | ||
| Q1 24 | $164.7M | $51.0M |
总资产ESCAPBYI
| Q4 25 | $222.1M | $216.3M | ||
| Q3 25 | $232.5M | $202.9M | ||
| Q2 25 | $218.3M | $194.9M | ||
| Q1 25 | $222.1M | $196.2M | ||
| Q4 24 | $226.3M | $213.3M | ||
| Q3 24 | $244.9M | $220.7M | ||
| Q2 24 | $243.1M | $205.0M | ||
| Q1 24 | $256.3M | $214.1M |
负债/权益比ESCAPBYI
| Q4 25 | 0.11× | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | 0.15× | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.9M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $13.7M | $14.4M |
| 自由现金流率自由现金流/营收 | 21.8% | 19.1% |
| 资本支出强度资本支出/营收 | 2.0% | 0.0% |
| 现金转化率经营现金流/净利润 | 4.02× | — |
| 过去12个月自由现金流最近4个季度 | $28.5M | $41.7M |
8季度趋势，按日历期对齐
经营现金流ESCAPBYI
| Q4 25 | $14.9M | $14.4M | ||
| Q3 25 | $-965.0K | $9.7M | ||
| Q2 25 | $13.3M | $14.1M | ||
| Q1 25 | $3.8M | $3.6M | ||
| Q4 24 | $12.3M | $15.6M | ||
| Q3 24 | $10.5M | $11.0M | ||
| Q2 24 | $13.3M | $1.0M | ||
| Q1 24 | $7.0K | $11.2M |
自由现金流ESCAPBYI
| Q4 25 | $13.7M | $14.4M | ||
| Q3 25 | $-1.3M | $9.7M | ||
| Q2 25 | $12.9M | $14.1M | ||
| Q1 25 | $3.2M | $3.6M | ||
| Q4 24 | $11.7M | $15.6M | ||
| Q3 24 | $10.2M | $11.0M | ||
| Q2 24 | $12.5M | $1.0M | ||
| Q1 24 | $-350.0K | — |
自由现金流率ESCAPBYI
| Q4 25 | 21.8% | 19.1% | ||
| Q3 25 | -1.9% | 17.7% | ||
| Q2 25 | 23.7% | 26.8% | ||
| Q1 25 | 5.9% | 7.7% | ||
| Q4 24 | 18.4% | 26.4% | ||
| Q3 24 | 15.0% | 13.7% | ||
| Q2 24 | 20.0% | 2.1% | ||
| Q1 24 | -0.6% | — |
资本支出强度ESCAPBYI
| Q4 25 | 2.0% | 0.0% | ||
| Q3 25 | 0.4% | 0.0% | ||
| Q2 25 | 0.8% | 0.0% | ||
| Q1 25 | 1.0% | 0.1% | ||
| Q4 24 | 0.9% | 0.0% | ||
| Q3 24 | 0.5% | 0.0% | ||
| Q2 24 | 1.3% | 0.0% | ||
| Q1 24 | 0.6% | 0.0% |
现金转化率ESCAPBYI
| Q4 25 | 4.02× | — | ||
| Q3 25 | -0.17× | 1.10× | ||
| Q2 25 | 7.28× | 2.41× | ||
| Q1 25 | 1.45× | 1.21× | ||
| Q4 24 | 4.55× | — | ||
| Q3 24 | 1.85× | 0.54× | ||
| Q2 24 | 4.67× | — | ||
| Q1 24 | 0.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
